Goldman Sachs’s Climb Bio, Inc. Common Stock CLYM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $250K | Buy |
201,312
+80,570
| +67% | +$99.9K | ﹤0.01% | 4618 |
|
|
2025
Q1 | $147K | Sell |
120,742
-4,562
| -4% | -$5.57K | ﹤0.01% | 4744 |
|
|
2024
Q4 | $226K | Buy |
125,304
+66,258
| +112% | +$119K | ﹤0.01% | 4620 |
|
|
2024
Q3 | $301K | Buy |
+59,046
| New | +$301K | ﹤0.01% | 4342 |
|
|
2022
Q3 | – | Sell |
-162,792
| Closed | -$492K | – | 5693 |
|
|
2022
Q2 | $492K | Sell |
162,792
-2,295
| -1% | -$6.94K | ﹤0.01% | 4389 |
|
|
2022
Q1 | $1.39M | Buy |
165,087
+964
| +0.6% | +$8.09K | ﹤0.01% | 3869 |
|
|
2021
Q4 | $1.72M | Sell |
164,123
-1,829
| -1% | -$19.1K | ﹤0.01% | 3606 |
|
|
2021
Q3 | $2.98M | Buy |
+165,952
| New | +$2.98M | ﹤0.01% | 3174 |
|